← Eichor
Study identifier: NCT05686447 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis

Condition: Monoclonal Gammopathies · Multiple Myeloma · M-protein  ·  Sponsor: Zhujiang Hospital

PhaseN/A
Planned participants200
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

To provide a comprehensive MALDI-TOF mass spectrometry method for detecting, characterizing, and quantifying M-protein, and to track M-protein in a very sensitive and specific manner during patient treatment, providing a more precise test for diagnosing disease and monitoring patient response to treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Nianyi Zeng  ·  13928801657  ·  zengny1@i.smu.edu.cn

Hongwei Zhou, Professor  ·  18688489622  ·  hzhou@smu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Zhujiang Hospital of Southern Medical UniversityGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05686447